Luminal and basal-like breast cancer cells show increased migration induced by hypoxia, mediated by an autocrine mechanism

[1]  K. Zänker,et al.  Tumour reactions to hypoxia. , 2010, Current molecular medicine.

[2]  Jie Zhou,et al.  microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling , 2010, Proceedings of the National Academy of Sciences.

[3]  A. Mantovani,et al.  Cancer and Inflammation: Implications for Pharmacology and Therapeutics , 2010, Clinical pharmacology and therapeutics.

[4]  R. Hoffman,et al.  Human Breast Cancer Cell Lines Co-Express Neuronal, Epithelial, and Melanocytic Differentiation Markers In Vitro and In Vivo , 2010, PloS one.

[5]  S. Kurtz,et al.  Selective regain of egfr gene copies in CD44+/CD24-/low breast cancer cellular model MDA-MB-468 , 2010, BMC Cancer.

[6]  G. Ball,et al.  A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks , 2010, Breast Cancer Research and Treatment.

[7]  Y. Gong,et al.  Neutrophils promote inflammatory angiogenesis via release of preformed VEGF in an in vivo corneal model , 2010, Cell and Tissue Research.

[8]  Harris Markomanolaki,et al.  Hypoxia-inducible factor-1α and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients , 2009, Breast Cancer Research.

[9]  B. Nordenskjöld,et al.  Hypoxia, Snail and incomplete epithelial–mesenchymal transition in breast cancer , 2009, British Journal of Cancer.

[10]  John D. Minna,et al.  Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery , 2009, PloS one.

[11]  M. Jo,et al.  Reversibility of Epithelial-Mesenchymal Transition (EMT) Induced in Breast Cancer Cells by Activation of Urokinase Receptor-dependent Cell Signaling* , 2009, The Journal of Biological Chemistry.

[12]  I. Ellis,et al.  Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes , 2009, Clinical Cancer Research.

[13]  Sonja Loges,et al.  Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. , 2009, Cancer cell.

[14]  K. Pantel,et al.  Two-dimensional differential gel electrophoresis of a cell line derived from a breast cancer micrometastasis revealed a stem/ progenitor cell protein profile. , 2009, Journal of proteome research.

[15]  S. Fox,et al.  The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy , 2009, British Journal of Cancer.

[16]  E. Yagüe,et al.  Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. , 2009, Pharmacogenomics.

[17]  Peter Kazanzides,et al.  A robotic system for 18F-FMISO PET-guided intratumoral pO2 measurements. , 2009, Medical physics.

[18]  T. Elkhodary,et al.  Basal vs. luminal a breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers , 2009, Medical oncology.

[19]  D. Waugh,et al.  The Interleukin-8 Pathway in Cancer , 2008, Clinical Cancer Research.

[20]  G. Semenza.  Hypoxia‐inducible factor 1 and cancer pathogenesis , 2008, IUBMB life.

[21]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[22]  Takuya Moriya,et al.  Expression of basal keratins and vimentin in breast cancers of young women correlates with adverse pathologic parameters , 2008, Modern Pathology.

[23]  Tanja Fehm,et al.  Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance , 2008, Breast Cancer Research.

[24]  A. Cano,et al.  A hypoxic twist in metastasis , 2008, Nature Cell Biology.

[25]  M. Bache,et al.  Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies. , 2008, Current medicinal chemistry.

[26]  S. Fox,et al.  Breast tumour angiogenesis , 2007, Breast Cancer Research.

[27]  Harry Bartelink,et al.  Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas , 2007, Breast Cancer Research.

[28]  Ulrich Lehmann,et al.  MDA-MB-435: The questionable use of a melanoma cell line as a model for human breast cancer is ongoing , 2007, Cancer biology & therapy.

[29]  P. Bonnier,et al.  Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. , 2007, Human pathology.

[30]  Alain Chédotal,et al.  Chemotropic axon guidance molecules in tumorigenesis. , 2007, Progress in experimental tumor research.

[31]  Helen H. W. Chen,et al.  Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer. , 2007, Breast cancer research and treatment.

[32]  Chad J. Creighton,et al.  MDA-MB-435 cells are derived from M14 Melanoma cells––a loss for breast cancer, but a boon for melanoma research , 2007, Breast Cancer Research and Treatment.

[33]  Helen H. W. Chen,et al.  Hypoxia-inducible factor-1α correlates with MET and metastasis in node-negative breast cancer , 2007, Breast Cancer Research and Treatment.

[34]  D. Newgreen,et al.  Induction of epithelial to mesenchymal transition in PMC42-LA human breast carcinoma cells by carcinoma-associated fibroblast secreted factors , 2007, Breast Cancer Research.

[35]  J. Dering,et al.  Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro , 2007, Breast Cancer Research and Treatment.

[36]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[37]  F. Bertucci,et al.  Gene expression profiling of breast cell lines identifies potential new basal markers , 2006, Oncogene.

[38]  C. Keller-Peck,et al.  Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. , 2005, Cancer research.

[39]  Erwin G. Van Meir,et al.  The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. , 2005, Neuro-oncology.

[40]  C. Kaltschmidt,et al.  Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs , 2004, International journal of cancer.

[41]  Richard P. Hill,et al.  Acute Hypoxia Enhances Spontaneous Lymph Node Metastasis in an Orthotopic Murine Model of Human Cervical Carcinoma , 2004, Cancer Research.

[42]  Peter T. Nelson,et al.  Comparative Measurements of Hypoxia in Human Brain Tumors Using Needle Electrodes and EF5 Binding , 2004, Cancer Research.

[43]  T. L. Drell,et al.  Effects of Neurotransmitters on the Chemokinesis and Chemotaxis of MDA-MB-468 Human Breast Carcinoma Cells , 2003, Breast Cancer Research and Treatment.

[44]  F. Entschladen,et al.  Myosin regulation in the migration of tumor cells and leukocytes within a three-dimensional collagen matrix , 2004, Cellular and Molecular Life Sciences CMLS.

[45]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[46]  K. Zanker,et al.  Signal processing in migrating T24 human bladder carcinoma cells: Role of the autocrine interleukin‐8 loop , 2002, International journal of cancer.

[47]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[48]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[49]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[50]  S. J. Holt,et al.  Microculture tetrazolium assays: a comparison between two new tetrazolium salts, XTT and MTS. , 1995, Journal of immunological methods.

[51]  Robert Clarke,et al.  Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines , 1992, Journal of cellular physiology.

[52]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.